Test Price
2,800 AED✅ Home Collection Available
ZIC1 Gene Craniosynostosis Type 6 Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary: This advanced genetic test utilizes Next Generation Sequencing (NGS) to provide comprehensive analysis of the ZIC1 gene associated with craniosynostosis type 6. Performed in ISO 9001:2015 accredited laboratories, the assay delivers 99.9% diagnostic sensitivity. The service includes pre‑ and post‑test genetic counselling, VIP mobile phlebotomy with temperature‑controlled cold‑chain home collection (daily 8 AM – 11 PM), and DHA‑licensed clinical interpretation.
Test Overview & Methodology
The ZIC1 Gene Craniosynostosis Type 6 Genetic Test is a high‑precision single‑gene sequencing assay designed to detect pathogenic variants in the ZIC1 gene associated with autosomal dominant craniosynostosis type 6 (OMIM 616602). This test uses Next Generation Sequencing (NGS) technology to achieve comprehensive coding‑region coverage, including exon‑intron boundaries, enabling definitive molecular diagnosis for pediatric and neonatal patients presenting with dysmorphology and premature cranial suture fusion. Early molecular diagnosis enables timely neurosurgical planning and genetic counselling for recurrence risk assessment.
| Feature | Our Test (NGS – ZIC1) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% analytical sensitivity; full coding region + splice sites | ~99.0%; limited to targeted amplicons only |
| Methodology | NGS with 100× mean depth | Bidirectional Sanger Sequencing |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Sample Type | Whole Blood (EDTA) / Extracted DNA / FTA Card | Whole Blood (EDTA) only |
| Cost | 2,800 AED | 1,800 – 2,200 AED (limited coverage) |
Accepted Specimens: Whole Blood (EDTA), Extracted DNA, or One Drop of Blood on FTA Card. Pre‑Test Information: A comprehensive clinical history and a genetic counselling session with a detailed pedigree chart are mandatory. Please disclose all current medications, supplements, and herbal preparations during the pre‑test consultation.
Physician Insight & Safety Protocols
"Genetic testing for craniosynostosis is a deeply personal and clinically significant decision for any family. As a clinical geneticist, I emphasize that a positive ZIC1 result is not a diagnosis in isolation—it must be correlated with clinical findings, imaging studies, and a thorough dysmorphology assessment. My commitment is to ensure every patient receives compassionate, evidence‑based interpretation that guides timely neurosurgical and developmental intervention."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Clinical Notice: Do not discontinue any prescribed medication or alter your child’s treatment regimen without consulting your treating physician. This genetic test is a diagnostic aid and does not replace ongoing clinical management.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide informed consent from a legal guardian (mandatory for minors under UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Exclusion: Active febrile illness or acute infection at time of sample collection—reschedule when clinically stable.
- Exclusion: Recent blood transfusion (within 4 weeks) may interfere with germline DNA analysis.
- ER Red Flag: If your child exhibits signs of raised intracranial pressure—persistent vomiting, severe headache, lethargy, or sunsetting eyes—seek immediate emergency medical attention. Do not wait for genetic test results.
- ER Red Flag: New‑onset seizures, bulging fontanelle, or rapid head circumference increase warrant urgent neurosurgical evaluation.
Patient FAQ & Clinical Guidance
1. What is the ZIC1 gene test, and why is it performed?
The ZIC1 NGS test analyzes the complete coding sequence of the ZIC1 gene to identify pathogenic mutations causing craniosynostosis type 6, a condition where an infant’s skull sutures fuse prematurely, potentially restricting brain growth. Early molecular diagnosis enables timely neurosurgical planning and genetic counselling for recurrence risk assessment in future pregnancies.
2. How accurate is this genetic test compared to older methods?
This NGS‑based test delivers greater than 99.9% analytical sensitivity and specificity, surpassing traditional Sanger sequencing by capturing deep intronic regions, copy number variations, and mosaic variants that single‑amplicon methods frequently miss. The assay is validated against international genomic interpretation standards including ACMG/AMP variant classification guidelines.
3. Is home sample collection available across all UAE emirates?
Yes, our ISO‑certified cold‑chain home collection service operates seven days a week from 8 AM to 11 PM across Dubai, Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain. A certified pediatric phlebotomist arrives at your location with temperature‑controlled transport equipment, ensuring sample integrity from collection to laboratory accessioning within 120 minutes.
UAE Regulatory & Data Privacy Adherence
- Licensed by Dubai Health Authority (DHA) – Facility License No. 1143
- Compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – all genomic data stored on encrypted, UAE‑sovereign servers
- Compliant with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Patient consent governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability
- ISO 9001:2015 Certified – Certificate No. INT/EGQ/2509DA/3139
- Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE
Clinical & Logistical Metadata
| Test Name | ZIC1 Gene Craniosynostosis Type 6 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks from sample receipt |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) / Extracted DNA / Dried Blood Spot (FTA Card) |
| Methodology Used | Next Generation Sequencing (NGS) – 100× mean depth, full coding region + splice sites |
| ICD-10-CM Code | Q75.0 (Craniosynostosis) |
| LOINC Code | 81247-9 (ZIC1 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Lab Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians